cover image: Buprenorphine Formulations for the Treatment of Opioid Use Disorders

Premium

20.500.12592/m9ct21

Buprenorphine Formulations for the Treatment of Opioid Use Disorders

31 Jul 2017

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] The purpose of this report is to evaluate the clinical effectiveness, cost-effectiveness and evidence-based guidelines for the use of newer and unique buprenorphine formulations in patients with OUD. [...] SUMMARY WITH CRITICAL APPRAISAL Buprenorphine Formulations for the Treatment of Opioid Use Disorders 3 Research Question 1. What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone formulations for the treatment of opioid use disorders? [...] The proportion of the cohort relapsing was based on the proportion of patients in the RCT who reported being primary users of heroin. [...] Summary of Findings The overall findings are summarized below and detailed findings from the individual studies are provided in Appendix 4. What is the comparative clinical effectiveness of buprenorphine formulations for the treatment of patients with opioid use disorder?
health economics guideline medical research medicine methadone pharmacology health care randomized controlled trial therapy substance abuse addiction rcts abuse dependence placebo health sciences naloxone opioid buprenorphine opioid use disorder buprenorphine/naloxone opioid use disorders
ISSN
19228147
Pages
32
Published in
Ottawa, ON, CA

Related Topics

All